Nutriband Founder Returns as CEO to Lead Final Development of AVERSA Fentanyl Patch

Nutriband Inc. (NASDAQ: NTRB) announced that company founder Gareth Sheridan has resumed his role as CEO, effective immediately, following a temporary period during which Co-Founder and Chairman Serguei Melnik served in the position. Sheridan will lead the company through its final 2025 development framework toward an expected 2026 New Drug Application (NDA) filing for AVERSA Fentanyl, the company's flagship abuse-deterrent opioid patch. This leadership transition comes at a critical juncture as the company advances its primary pharmaceutical product toward regulatory submission.

The AVERSA Fentanyl patch represents a significant innovation in pain management with important public health implications. Designed specifically to deter misuse and accidental exposure, the technology addresses a critical need in the ongoing opioid crisis. The patch incorporates proprietary AVERSA technology that can be integrated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. This technological approach could potentially transform how controlled substances are delivered through transdermal systems.

Market projections for AVERSA Fentanyl indicate substantial commercial potential, with peak annual U.S. sales estimated between $80 million and $200 million. These figures reflect the significant market need for abuse-deterrent formulations amid growing regulatory pressure and public health concerns surrounding opioid medications. The company's intellectual property position is robust, with the AVERSA technology protected by patents in 46 countries, including the United States, Europe, and Japan, providing global protection for this innovative approach to drug delivery.

Investors can access additional company information through the corporate newsroom available at https://ibn.fm/NTRB, which provides ongoing updates about Nutriband's development progress and corporate announcements. The company maintains its corporate website at https://www.nutriband.com where stakeholders can find comprehensive information about the company's transdermal pharmaceutical development portfolio. The full press release detailing the leadership transition and development timeline is accessible at https://ibn.fm/3r3N9 for those seeking complete details about this corporate announcement.

The timing of Sheridan's return to the CEO position underscores the strategic importance of the final development phase leading to the anticipated 2026 NDA submission. With the opioid crisis continuing to pose significant public health challenges, regulatory agencies have shown increased interest in abuse-deterrent formulations that can help mitigate risks associated with potent pain medications. The AVERSA technology platform represents Nutriband's core competitive advantage in this specialized pharmaceutical segment, positioning the company to potentially capture meaningful market share in the abuse-deterrent transdermal patch category.